Език: EN EN
Започни търсене
Търсене, моля изчакайте...
Филтри 1
Изчисти
Статус
Фаза
Цел
Пол
Възраст
Държава
Филтри 1
Изчисти
Статус
Фаза
Цел
Пол
Възраст
Държава
Активни:
Намерени 282 изпитвания Стр. 4 от 15
Набира участници Фаза 3
A Prospective, Multi-National, Randomized, Double-Blind, Crossover Study to Evaluate the Efficacy and Safety of Gadopiclenol-enhanced MRA Compared to Gadoterate Meglumine-enhanced MRA in the Assessment of Steno-occlusive Disease in Adult Patients with Suspected Vascular Disease
Suspected Vascular Disease of supra-aortic (carotid/vertebrobasilar) peripheral or abdominal/renal arteries

Trial status: Authorised Diagnostic performance indicators, namely sensitivity and specificity for detecting clinically significant steno-occlusive disease of different vascular territories.

Начало: 15.04.2026 Възраст: от 18 г.
Czech Republic, France, Germany +4 Guerbet, Bracco Imaging S.p.A. 2024-518835-13-00
Набира участници Фаза 2
Multicentre, open-label, phase 1/2 study of LB-208, selective antagonist of the serotonin 5-hydroxytryptamine receptor 1B (HTR1B), in adults with relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r higher-risk (HR) myelodysplastic syndrome (MDS)
Relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r higher-risk (HR) myelodysplastic syndrome (MDS)

Trial status: Authorised Plasma concentration-time profiles, and PK parameters of LB-208., Response according to the revised European LeukemiaNet (ELN) Response Criteria in AML (Döhner et al., 2022) and revised International Working Group 2023 (IWG 2023) in HR-MDS (Zeidan, Platzbecker, et al., 2023). Response for all patients will be assessed by the site Investigators. Safety, and toxicity will be described by observed frequency and severity graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0., including dose limiting toxicity (DLT) rate, adverse events (AEs), serious adverse events (SAEs), and AEs leading to discontinuation.

Начало: 15.04.2026 Възраст: от 18 г.
Spain Aop Orphan Pharmaceuticals GmbH 2025-523396-38-00
Набира участници Фаза 3
A Phase 3 randomized, double-blind, placebo-controlled, parallel group, multicenter study with open-label extension to evaluate the efficacy and safety of fenfluramine hydrochloride in study participants with Rett syndrome
Rett syndrome

Trial status: Authorised Change from Baseline to Week 14 in Patient-Reported Outcomes Measurement Information System-Sleep Disturbance (PROMIS-SD) score, Change from Baseline to Week 14 in Observer-Reported Communication Ability (ORCA) score, Caregiver Global Impression of Change – Seizure (CaGIC-Seizure) score at Week 14, Incidence of Treatment-emergent adverse event (TEAEs), Incidence of serious TEAEs, Incidence of TEAEs leading to discontinuation, Incidence of related TEAEs, Change from Baseline in QT interval corrected using Fridericia’s formula (QTcF) interval on 12-lead ECG at Week 14, Treatment-emergent Doppler Echocardiogram (ECHO) results meeting the Food and Drug Administration (FDA) case definition of drug-associated valvular heart disease (VHD), Treatment-emergent Doppler ECHO results meeting the FDA case definition of pulmonary arterial hypertension (PAH) >35mmHg Change from Baseline to Week 14 in Rett Syndrome Behaviour Questionnaire (RSBQ) Total Score, Clinical Global Impression of Change (CGIC) Score at Week 14

Начало: 15.04.2026 Възраст: 18–64 г.
Belgium, France, Germany +2 UCB Biosciences Inc. 2025-523157-34-00
Набира участници Фаза 1
A clinical trial to learn about the effects of DAK539 on the blood levels of repaglinide, midazolam, drospirenone, and ethinyl estradiol in people with advanced cancer
Patients with advanced malignancies

Trial status: Authorised

Начало: 14.04.2026 Възраст: от 18 г.
France, Italy, Spain Novartis Pharma AG 2025-521000-22-00
Набира участници Фаза 2
A Phase 1/2 open-label, multicenter study of oral GSK5460025 alone or in combination with other anti-cancer agents in adult participants with Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) solid tumors.
Neoplasms Colorectal

Trial status: Authorised Part 1: Plasma concentrations for GSK5460025, Part 1: Area under the concentration-time curve (AUC) for GSK5460025, Part 1: Time to maximum concentration (Tmax) for GSK5460025, Part 1: Number of participants with clinically important changes in laboratory parameters, Electrocardiogram (ECGs), and vital signs per dose level, Part 2: Number of participants with TESAEs and TEAEs by severity, Part 2: Number of participants with TEAEs leading to dosage modifications, Part 2: Number of participants with clinically important changes in laboratory parameters, ECGs, and vital signs, PFS is defined as time from first dose to progressive disease (as assessed per RECIST 1.1 by Investigator assessment) or death from any cause, whichever is earlier, DoR is defined as time from first documented PR or CR to progressive disease (as assessed per RECIST 1.1 by investigator assessment) or death from any cause, whichever is earlier for participants who have achieved a confirmed CR or PR., Part 2: Plasma concentration of GSK5460025 Part 1: Number of participants with dose limiting toxicities (DLTs) per dose level, Part 1: Number of participants with treatment emergent serious adverse events (TESAEs) and treatment emergent adverse events (TEAEs) by severity per dose level, Part 1: Duration of TESAEs and TEAEs per dose level, Part 1: Number of participants with TESAEs and TEAEs by severity per dose level during DLT observation period, Part 1: Number of participants with dosage modifications due to TEAEs per dose level, "Part 2: Objective Response Rate (ORR) ORR is defined as percentage of participants with confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) by investigator assessment."

Начало: 14.04.2026 Възраст: от 18 г.
Denmark, France, Italy +3 Glaxosmithkline Research & Development Limited 2025-522318-21-00
Набира участници Фаза 2
Randomized, Double-Blinded, Vehicle-Controlled, Parallel Group, Adaptive Proof-of-concept, Dose-selecting Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Intranasal Cenegermin (recombinant human Nerve Growth Factor [rhNGF]) in Adult Participants with subacute moderate to severe Traumatic Brain Injury (TBI).
Subacute Moderate to Severe Traumatic Brain Injury (TBI)

Trial status: Authorised 1. Sliding and good outcome in Glasgow Outcome Scale – Extended at month 6., 2. Through 12 months following the first administration of investigational product., 3. Incidence of treatment-emergent serious and non-serious adverse events, and adverse events of special interest., 4. Participant incidence of study discontinuation for tolerability reasons., 5. Change from baseline on vital signs, 12-lead ECG results, clinical laboratory assessments, physical examinations, brain MRI, C-SSRS and blood levels of ADA. 1. Incidence of treatment-emergent serious and non-serious adverse events through 6 months following the first intranasal administration of cenegermin.

Начало: 14.04.2026 Възраст: от 18 г.
Denmark, Finland, France +5 Dompe' Farmaceutici S.p.A. 2025-522692-29-00
Набира участници Фаза 2
Phase 1/2A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients with Advanced Solid Tumors
advanced solid tumors

Trial status: Authorised Phase 1 - Objective Response Rate (ORR), Phase 1 - Duration of response (DOR), Phase 1 - Disease control rate (DCR), Phase 1 - Progression free survival (PFS), Phase 1 and 2A- Plasma concentrations of OTP-01 as a function of time post-dosing, Phase 1 and 2A- PK parameters (area under the curve [AUC], maximum plasma concentration [Cmax], minimum plasma concentration [Cmin], time of maximum concentration [Tmax], half-life [t1/2], clearance [CL]) for single (first) dose and multiple doses Phase 1 - Inclusive of all aspects of safety, tolerability, biologic activity, PK, pharmacodynamics (PD) and preliminary efficacy, Phase 1 - Frequency and severity of adverse events (AEs) and serious adverse events (SAEs), Phase 2A - Objective Response Rate (ORR), Phase 2A - Duration of response (DOR), Phase 2A - Disease control rate (DCR), Phase 2A - Progression free survival (PFS), Phase 2A - Frequency and severity of AEs and SAEs

Начало: 14.04.2026 Възраст: от 18 г.
Ireland, Portugal, Spain Ottimo Pharma Limited 2025-524111-37-00
Набира участници Фаза 2
A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina-S) in Participants with Non-Small Cell Lung Cancer
Locally advanced or metastatic Non-Small Cell Lung Cancer

Trial status: Authorised 1.Duration of Response (DOR) per RECIST v1.1 as Assessed by Investigator [Time Frame: Approximately 4 years], 2.Disease Control Rate (DCR) per RECIST v1.1 as Assessed by Investigator [Time Frame: Approximately 4 years], 3.Progression-free Survival (PFS) [Time Frame: Approximately 4 years], 4.Overall Survival (OS) [Time Frame: Approximately 4 years], 5.Maximum (Peak) Observed Serum Drug Concentration (Cmax) of Rina-S Related Analytes [Time Frame: Approximately 12 months], 6.Time to Reach Maximum (Peak) Serum Drug Concentration (Tmax) of Rina-S Related Analytes[Time Frame: Approximately 12 months], 7.Number of Participants with Antidrug Antibodies (ADAs) [Time Frame: Approximately 12 months], 8.Number of Participants with Treatment-emergent Adverse Events (TEAEs) [Time Frame: Approximately 4 years] Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as Assessed by Investigator [Time Frame: Approximately 3 years]

Начало: 14.04.2026 Възраст: от 18 г.
Belgium, France, Germany +5 Genmab A/S 2025-522107-18-00
Набира участници Фаза 2
C6231002 - A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF 08049820 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Atopic Dermatitis

Trial status: Authorised Response based on achieving EASI75 (≥75% improvement from baseline) at scheduled time points, Percent change from baseline in EASI total score at scheduled time points other than Week 12, Response based on achieving vIGA score of clear (0) or almost clear (1) (on a 5-point scale) and a reduction from baseline of ≥2 points at scheduled time points, Response based on achieving ≥4 points of reduction from baseline in weekly averages of Peak Pruritus Numerical Rating Scale (PP-NRS4) at scheduled time points, Incidence of treatment emergent adverse events (AEs), serious adverse events (SAEs), and clinically significant changes in laboratory tests, vital signs, and electrocardiograms (ECGs) Percent change from baseline in EASI total score at Week 12

Начало: 14.04.2026 Възраст: 18–64 г.
Bulgaria, Czech Republic, France +2 Pfizer Inc. 2025-522965-31-00
Набира участници Фаза 2
A Phase 2, multicenter, open label, non-randomized study to evaluate the efficacy and safety of extended dosing of belantamab mafodotin in different combinations with standard of care regimens in participants with relapsed-refractory multiple myeloma (DREAMM-15)
Relapsed or Refractory Multiple Myeloma

Trial status: Authorised • CRR, defined as the percentage of participants with a confirmed CR or better. • MRD negativity rate, defined as the percentage of participants who achieve MRD negative status at least once during the time of confirmed CR or better response as per IMWG. • DoR, defined as the time from first documented evidence of PR or better until PD or death due to any cause., • Incidence and severity of AEs and SAEs; • Incidence of AEs leading to dose modifications or study intervention discontinuation; • Incidence and severity of ocular findings on ophthalmic exam (changes in VA and cornea findings)., OSDI, PRO-CTCAE (ocular), PROSIM-Q, and CTCAEs (eye disorders – other) concordance with KVA ORR, defined as the percentage of participants with a confirmed PR or better (i.e., PR, VGPR, CR, sCR).

Начало: 13.04.2026 Възраст: от 18 г.
France, Germany, Greece +2 Glaxosmithkline Research & Development Limited 2025-523117-28-00
Набира участници Фаза 3
A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Seizures
Focal Epilepsy

Trial status: Authorised Change from baseline in seizure frequency from the Observation Period to the Treatment Period as assessed across the vormatrigine 20 mg, 30 mg and 40 mg dose groups, Seizure Freedom, during the last period, Time to achieve 50% seizure reduction from the Observation Period, Change from baseline in monthly focal seizure frequency from the Observation Period to each month of the Treatment Period for vormatrigine compared with placebo, Impact of vormatrigine compared to placebo on PGI-C and CGI-C, Incidence and severity of TEAEs, including discontinuation of study drug due to TEAEs, Changes in vital sign measurements, Changes in clinical laboratory results, Changes in ECG parameters, Changes in suicidality, as assessed by C-SSRS 50% Responder, defined as at least a 50% reduction in focal seizure frequency from the Observation Period to the Treatment Period

Начало: 10.04.2026 Възраст: от 18 г.
Czech Republic, Germany, Italy +2 Praxis Precision Medicines Inc. 2025-524038-24-00
Набира участници Фаза 2
A Phase 2b, Randomized, Double blind, Placebo controlled, Parallel group, Multicenter, Dose ranging Study Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Adult Participants with Uncontrolled Moderate to Severe Eosinophilic Asthma
Uncontrolled Moderate to Severe Eosinophilic Asthma

Trial status: Authorised Change from baseline to Week 12 in post-bronchodilator FEV1., Change from baseline to Week 12 in ACQ-5 score, Change from baseline to Week 12 in the AQLQ(S) Global Score, Incidence of TEAEs, Incidence of treatment-emergent SAEs, Plasma PK parameter estimates of KT-621 derived from plasma concentration time data Change from baseline to Week 12 in pre-bronchodilator FEV1.

Начало: 10.04.2026 Възраст: от 18 г.
Austria, Belgium, Germany +5 Kymera Therapeutics Inc. 2025-523180-38-00
Набира участници Фаза 2
C6461020 - An Interventional Open-Label Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of PF-08634404 in combination with Different Anticancer Agents in Participants with Advanced Solid Tumors
Advanced Solid Tumors

Trial status: Authorised Phase 1 Safety Run-In: Confirmed ORR per RECIST v1.1 by investigator, DCR per RECIST v1.1 by investigator, DOR per RECIST v1.1 by investigator, PFS per RECIST v1.1 by investigator, OS, Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing., Predose and/or postdose concentrations of PF-08634404, SV, and PF-08046054., Incidence of ADA against PF-08634404, SV, and PF-08046054., Phase 2 Dose Optimization and Dose Expansion: DOR per RECIST v1.1 by investigator, DCR per RECIST v1.1 by investigator, PFS per RECIST v1.1 by investigator, OS, Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing., Predose and/or postdose concentrations of PF-08634404, SV, and PF-08046054., Incidence of ADA against PF-08634404, SV, and PF-08046054. Phase 1 Safety Run-In: AEs as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention., DLTs., Phase 2 Dose Optimization and Dose Expansion: Confirmed ORR per RECIST v1.1 by investigator, AEs as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention.

Начало: 09.04.2026 Възраст: от 18 г.
France, Germany, Italy +1 Pfizer Inc. 2025-523526-40-00
Набира участници Фаза 2
A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM). (MEZI-KD)
Patients with relapsed/refractory symptomatic multiple myeloma (MM)

Trial status: Authorised Overall Survival (OS) defined as the time from inclusion to time of death due to any cause, Overall Response Rate (ORR) defined as the percentage of participants who achieve best response of partial response (PR) or better according to the IMWG Uniform Response Criteria for Multiple Myeloma, Rate of very good partial response (VGPR) or better (VGPRR) defined as the percentage of participants who achieve best response of VGPR or better according to the IMWG Uniform Response Criteria for Multiple Myeloma, Rate of complete response (CR) or better (CRR) defined as the percentage of participants who achieve best response of CR or better according to the IMWG Uniform Response Criteria for Multiple Myeloma, Time to Response (TTR) defined as the time from inclusion on to the first documentation of response (PR or better), Duration of Response (DOR) defined as the time from the first documentation of response (PR or better) to the first documentation of progressive disease (PD) or death due to any cause, whichever occurs first, Time to Progression (TTP) defined as the time from inclusion to the first documentation of PD, Time to Next Treatment (TTNT) defined as the time from inclusion to the start of the next anti-myeloma treatment, To evaluate minimal residual disease (MRD) negativity rate in participants treated with 480Kd defined as the proportion of participants who achieve CR or better and are MRD negative (defined at a sensitivity of a minimum of 1 in 105 nucleated cells), To evaluate safety of 480Kd in participants with RRMM, defined as the type, frequency, seriousness and severity of adverse events (AEs), and relationship of AEs to study treatment, To evaluate cancer and multiple myeloma-related symptoms and health-related quality of life (HRQoL) using the European Organization for Research and Treatment of Cancer - Quality of Life C30 questionnaire (EORTC QLQ-C30) and the European Quality of Life Multiple Myeloma module (EORTC QLQ-MY20) in participants treated with 480Kd The progression-free survival defined as the time from inclusion to first documentation of progressive disease (PD) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma or death due to any cause, whichever occurs first

Начало: 08.04.2026 Възраст: от 18 г.
France Assistance Publique Hopitaux De Paris 2025-521090-14-00
Набира участници Фаза 2
ETOP 29-25 START-lung: A multicentre phase II trial of tarlatamab in patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2.
Patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2

Trial status: Authorised Objective response rate (ORR) according to RECIST v1.1, Duration of response (DoR), Disease control rate (DCR), Progression-free survival (PFS) according to RECIST v1.1, Incidence, nature, and severity of adverse events according to CTCAE v5, except for CRS and ICANS, that are graded according to the ASTCT criteria and TLS that are graded according to the Cairo-Bishop classification Overall survival rate at 12 months (12-month OS)

Начало: 08.04.2026 Възраст: от 18 г.
France, Greece, Italy +1 ETOP IBCSG Partners Foundation 2025-522288-13-00
Набира участници Фаза 1
A research study looking into how cagrilintide influences food intake and appetite in people with overweight or obesity
Obesity

Trial status: Authorised

Начало: 02.04.2026 Възраст: 18–64 г.
Germany Novo Nordisk A/S 2025-524206-15-00
Набира участници Фаза 3
EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY- BIASED ULTRA LONG-ACTING GLP-1RA IN PEOPLE WITH OVERWEIGHT OR OBESITY: A PHASE 3, MULTI-CENTER RANDOMIZED, CONTROLLED TRIAL (VESPER-4)
Obesity

Trial status: Authorised Change from baseline in body weight (kg) at Week 64, Occurrence at Week 64 of: • CCI % of reduction from baseline body weight • CCI% of reduction from baseline body weight • CCI % of reduction from baseline body weight • O CCI % of reduction from baseline body weight, Change from baseline at Week 64 in: • Fasting triglycerides (mg/dL) • O Non-high-density lipoprotein-cholesterol (non-HDL-C) (mg/dL), Change from baseline in SBP (mmHg) at Week 64, Change from baseline in Short Form 36 health survey (SF-36) physical function domain score at Week 64, Percent change from baseline in body weight at Week 84, Change from baseline in body weight (kg) at Week 84 Percent change from baseline in body weight at Week 64

Начало: 02.04.2026 Възраст: от 18 г.
Bulgaria, Czech Republic, Germany +5 Metsera Inc. 2025-523974-18-00
Набира участници Фаза 2
Phase 1/2 Investigation Of Novel Experimental Regimen in Amyotrophic Lateral Sclerosis (PIONEER-ALS): An Open-Label, Uncontrolled, Multicenter Study to Assess the Safety and Tolerability of Two Doses of VTx-002.
Amyotrophic Lateral Sclerosis

Trial status: Authorised Change in revised ALS Functional Rating Scale (ALSFRS-R) over 6 and 12 months, Time to permanent assisted ventilation, or death over 12 months, Change in slow vital capacity (SVC) over 6 and 12 months, Survival, Immunogenicity against adeno-associated virus (AAV) capsid Nature, incidence, severity, relatedness, seriousness, and outcome of treatment-emergent adverse events (TEAEs) including: o Laboratory values o Magnetic resonance imaging (MRI) findings o Treatment-induced Peripheral Neuropathy Assessment Scale (TNAS) o Assessment of cellular responses to both the vector and the transgene encoded protein o Columbia Suicide Severity Rating Scale (C-SSRS)

Начало: 31.03.2026 Възраст: от 18 г.
Belgium, Netherlands, Spain VectorY Therapeutics B.V. 2025-522697-37-00
Набира участници Фаза 2
Phase II study to improve sacituzumab govitecan tolerance with atropine in patients with advanced triple-negative and hormone receptor-positive/HER2-negative breast cancer (The SATROPIN Study).
Advanced triple-negative breast cancer (TNBC)

Trial status: Authorised Overall safety profile according to the NCI-CTCAE v.5.0 during the first two treatment cycles and the extended follow-up., Incidence of all grades diarrhea during the first two treatment cycles and during the extended follow-up, as assessed by the Investigator, with severity determined by NCI-CTCAE v.5.0., Incidence of all grades constipation during the first two treatment cycles and during the extended follow-up, as assessed by the Investigator, with severity determined by NCI-CTCAE v.5.0., Dose reduction rate, defined as the proportion of participants with dose reduction due to toxicity relative to the number of participants in the analysis set., Dose interruption rate, defined as the proportion of participants with dose interruption due to toxicity relative to the number of participants in the analysis set., Discontinuation rate, defined as the proportion of participants who discontinued Study treatment to any cause relative to the number of participants in the analysis set., rwPFS, defined as the time between start of treatment to date of disease progression or death documented in participant medical charts, whichever date came first., TTF, defined as the time from the start of treatment to its discontinuation for any reason, including disease progression, treatment-related toxicity, participant withdrawal, or death., TTF-Toxicity, defined as the time from the start of treatment to its discontinuation especially due to treatment-related adverse events (TEAEs). It excludes discontinuation for other reasons such as disease progression, participant withdrawal, or death unrelated to toxicity., OS, defined as the period from treatment initiation to death from any cause, as determined locally by the Investigator., Incidence of all grades constipation during the first two treatment cycles, as assessed by the Investigator, withseverity determined by the NCI-CTCAE v.6.0. Incidence of grade ≥2 diarrhea during the first two treatment cycles as assessed by the Investigator, with severity determined by the NCI-CTCAE v.5.0.

Начало: 30.03.2026 Възраст: от 18 г.
Portugal, Spain Medica Scientia Innovation Research S.L. 2025-524109-33-00
Набира участници Фаза 3
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator’s Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy
Endometrial Cancer Advanced Recurrent Metastatic or Primary Unresectable Endometrial Cancer

Trial status: Authorised Objective Response Rate (ORR), per RECIST v1.1, as Determined by BIRC, PFS, per RECIST v1.1, as determined by investigator assessment, ORR, per RECIST v1.1, as Determined by investigator assessment, Duration of Objective Response (DOR), per RECIST v1.1, as Determined by Investigator Assessment, DOR, per RECIST v1.1, as Determined by BICR, Number of Participants with Treatment-emergent Adverse Events (TEAEs), Change from Baseline in Global Health Status/Quality of Life (GHS/Qol), Time to Deterioration (TTD) in GHS/Qol 1. Progression-free survival (PFS) per Response Criteria in Solid Tumors (RECIST) v1.1, as Determined by independent central review (BICR) [Time Frame: Up to approximately 3 years], 2. Overall Survival (OS) [Time Frame: Up to approximately 3 years]

Начало: 26.03.2026 Възраст: от 18 г.
Belgium, Denmark, Finland +8 Genmab A/S 2024-519818-31-01
1 2 3 4 5 6 … 15